Postoperative pain management market seen reaching $67.6 billion by 2033

The global postoperative pain management market is projected to grow from $45.3 billion in 2026 to $67.6 billion by 2033, driven by more surgeries, broader use of multimodal care and stronger focus on recovery. The forecast points to rising demand for non-opioid therapies, better drug delivery systems and enhanced recovery protocols across hospitals and ambulatory surgery centers.

Why it matters: - Postoperative pain control can shorten hospital stays, improve recovery and support better treatment outcomes after surgery. - Rising surgical volumes, aging populations and more chronic disease are increasing demand for effective pain management. - The market is also shifting toward safer alternatives as providers look to reduce reliance on single-drug and opioid-heavy approaches.

What happened: - Persistence Market Research put the global postoperative pain management market at $45.3 billion in 2026. - The market is forecast to reach $67.6 billion by 2033. - The report projects a compound annual growth rate of 5.9% from 2026 to 2033. - The report highlights June 16, 2026 as the publication date. - The release includes a free sample report, a customization request page and a full report checkout page.

The details: - Multimodal pain management is gaining traction because it combines several therapeutic approaches to improve pain relief and reduce dependence on one medication class. - Technological advances in analgesic delivery systems are improving treatment effectiveness. - Hospitals remain the main end users because they perform the largest share of surgical procedures. - Ambulatory surgical centers are adopting more advanced pain management solutions as outpatient surgery grows and recovery times shrink. - The market is segmented by treatment approach, medication type, route of administration and healthcare setting. - The report flags North America as a major regional market because of advanced healthcare infrastructure, strong adoption of innovative therapies and high surgical volumes. - Europe is also a major market, supported by higher healthcare investment and patient-centered care. - Asia Pacific is emerging as a high-growth region because of expanding healthcare infrastructure, rising surgical volumes and better access to advanced medical treatments.

Between the lines: - The forecast suggests postoperative pain management is becoming a broader care workflow, not just a pharmacy decision. - Investment appears to be shifting toward non-opioid therapies, personalized pain strategies and newer delivery technologies. - Regulatory pressure and side-effect concerns may slow some drug categories, which could favor companies offering safer or more targeted options. - The market list points to a crowded competitive field that includes large drugmakers and specialized pain-treatment companies.

What's next: - Market growth is expected to continue as surgical volumes rise and hospitals expand enhanced recovery protocols. - Demand should increase for multimodal, non-opioid and personalized pain management products. - Product development and investment will likely focus on therapies that balance pain relief with fewer safety concerns. - Major companies named in the report include Pfizer, Johnson & Johnson, Baxter International, Abbott Laboratories, Pacira BioSciences, Mallinckrodt Pharmaceuticals, Hikma Pharmaceuticals, Teva Pharmaceutical Industries, Viatris and Fresenius Kabi.